Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

The mechanism of GLP-1 agonists is straightforward. They mimic the effects of the naturally occurring hormone, GLP-1, which regulates blood sugar and appetite in the body. While they are highly ...

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision to back out of its $1 billion ...

Research Triangle Park in North Carolina has emerged as one of the U.S’s most dynamic and rapidly expanding biotech hubs, home to a thriving ecosystem of established pharma companies, research ...

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex, and many ...

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as ...

AI has completely shifted the paradigm in the biotech industry. The past year has seen a gold rush in AI applications for the biopharma sector, for drug and protein discovery, or even treatment ...